Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).
Anna Maria Di Giacomo
Honoraria - Bristol-Myers Squibb
Antonio M Grimaldi
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck; Roche/Genentech
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck; Roche/Genentech
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Michele Del Vecchio
No relevant relationships to disclose
Ruggero Ridolfi
No relevant relationships to disclose
Francesco De Rosa
No relevant relationships to disclose
Federica De Galitiis
No relevant relationships to disclose
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; IGEA; Merck; Roche
Honoraria - Amgen; Bristol-Myers Squibb; IGEA; Merck; Roche
Francesco Cognetti
No relevant relationships to disclose
Maria Grazia Bernengo
Consultant or Advisory Role - Bristol-Myers Squibb
Paola Savoia
No relevant relationships to disclose
Michele Guida
No relevant relationships to disclose
Sabino Strippoli
No relevant relationships to disclose
Luca Galli
No relevant relationships to disclose
Mario Mandala
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Giorgio Parmiani
Consultant or Advisory Role - CureVac
Gaetana Rinaldi
No relevant relationships to disclose
Massimo Aglietta
No relevant relationships to disclose
Vanna Chiarion-Sileni
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb